U.S. Markets open in 4 hrs 16 mins

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.9896-0.0204 (-2.0198%)
At close: 4:00PM EDT
People also watch
BCRXINODVAXHEBARRY
  • j
    j
    j
    Placed Maynard aka Trub on ignore cause he won't shut up!
  • d
    derekdaponte
    derekdaponte
    What are the chances this does a reverse split at some point? If it does we are all screwed because then it will never recover
  • K
    KingJohn
    KingJohn
    I outed Trublurain (maynord,zach,flynn,dbird,etc,etc) over a month ago and she is still talking to herself..Lol! Seems she went bat sheet crazy since redbird cut her loose!
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = Undiscovered low float stock with 1000% upside Potential and more .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $18 Million
    Cash: $8 Million
    Price $0.37

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • J
    Jose
    Jose
    Somebody on this board wished that something crawled out of the swamp and dragged Trublurain and her make believe friends off,but it looks like that regrettably didn't happen.Best to just mute this loser and keep muting the alias's as they pop up.Her aka's include, but are not limited to Zach,Maynard,Rafel,BM,JamesFlynn,Dbird,Gianfranco,Smart,Stewart,Smile,So,Majic GD,Guy and so on!...............She is probably just a paid pumper and most likely works at corporate in Gaithersburg.A very sick and vile individual!
  • A
    Anthony
    Anthony
    Like if you wish Maynard G would fall in a ditch
  • K
    KingJohn
    KingJohn
    Trublurain,take all your aka's and just get lost. You poor little slug.
  • S
    Selassie
    Selassie
    Are you all still buying into their BS news reports? They have been doing this for over 5 yrs. BS reports to get people to buy. It's not going anywhere
  • D
    Diesel
    Diesel
    This stock has moved almost completely horizontal on a 1 year chart, I don't think I have ever seen this before.
  • t
    trublurain
    trublurain
    Keep this in mind: At any moment, this stock can jump straight up with the announcement of an obtained grant or partnership.
    ANYTIME AT ALL! Stay tuned.
  • R
    Richard
    Richard
    No Trub and her aka's this fine morning? Hopefully something crawled out of the swamp and dragged them off!
  • S
    Steve
    Steve
    Redplate Observations...

    A couple of months ago, Redplate predicted that Novavax would be $8 in 6 months. He said that this was based on 'previously published, functional data' on RSV Maternal data. (He indicated the data was from an April WHO presentation). Redplate even went so far as to say Novavax could reach $8 - $10.

    (BTW... Redplate worked for a vaccine company, as a top vaccine scientist, that was bought out by GSK for $1.5B, so he understands vaccines better than most.)

    Then... After the underwhelming 7/24 RSV Conference, Red backtracked on his predictions considerably, based on what he said were a lack of timelines for RSV.

    Then... On the 8/8 earnings call, the very compelling NanoFlu slides were released along with better timelines for RSV, and the announcement that Novavax was meeting with BARDA this week to discuss funding, after hitting all their 'hot buttons, with NanoFlu.

    It would seem we are now in a much stronger position than we were before Redplate started with his price predictions.

    Wondering what Dr Redplate thinks now, and if there's any path forward without a major Big Pharma partner &/or a buyout. Also... timing. I used to think any deal would have to wait until after an FDA early-peek of RSV maternal, but this NanoFlu data might be bigger than RSV.

    TIA
  • C
    Chris
    Chris
    Jose, and Richard, I think there are only about a half dozen of us left here. Just found out from my sources that Gianfranco , in addition to Green, Maynard, Trublurain, Zachattack and Daddybird are all the same poster.
  • J
    Jose
    Jose
    Up $ 03 cents! Sounds like party time!
    Imagepartyparadise
  • J
    Jose
    Jose
    Only down $.02 cents today.Winning! Lets party!!!!
    Imagepartyparadise
  • D
    Diesel
    Diesel
    Anyone think this stock will go up to $3-4 when flu vaccine season comes?
  • G
    Green
    Green
    from CC last week- we're scheduled to talk with all of the BARDA people next week, all the high-level people. And so we have a lot of visibility into that area.
  • C
    Chris
    Chris
    Rrrrrrrufffff-rrrrrrufffffffft. This dog won't hunt!!!!
  • C
    Chris
    Chris
    I see Trublu is out and about with his/her aliases, Zachattack and Maynardgkrebs. Simply the worst poster names ever....and corny as hell.
  • D
    Daddybird
    Daddybird
    Yet another Daddybird "Chris" impersonation: Good morning dummies, losers, bagholders, long fools, and night crawlers. Bend over longs because NVAX is one major POS. This is a cash burning pig that is slaughtering the longs. Pure junk! Anyone holding a long position is a fool. If you combined the intelligence of Dodobird, Trublurain, and Green it wouldn't even approach the IQ of an amoeba. This is a sham company of epic proportions. You longs will still be predicting a turnabout in one week, one year, and even after a decade of disappointments. The stock is a POS, management is a POS, their research protocols are a POS, and the research results are a POS. BWAHAHAHAHAHAHAHAHAHAHAHA! Meanwhile, I will be enjoying my view of the ocean from my estate in Ft. Lauderdale. If anyone wants to consult me about how to profit from shorting this pig, I will be in the local tavern room sipping a cold brew. You longs are LOSERS, LOSERS, LOSERS.